Published in Ann Rheum Dis on September 30, 2004
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Vertebral endplate signal changes (Modic change): a systematic literature review of prevalence and association with non-specific low back pain. Eur Spine J (2008) 2.25
Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis (2011) 1.68
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther (2008) 1.56
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis (2005) 1.37
Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis (2005) 1.21
Osteoimmunology and osteoporosis. Arthritis Res Ther (2011) 1.20
18F-fluoride PET/CT for detection of sacroiliitis in ankylosing spondylitis. Eur J Nucl Med Mol Imaging (2010) 1.14
A systematic critical review on MRI in spondyloarthritis. Arthritis Res Ther (2012) 0.92
Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol (2007) 0.90
Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis. BMC Musculoskelet Disord (2007) 0.88
[Imaging in ankylosing spondylitis]. Z Rheumatol (2007) 0.82
Imaging the spine in arthritis-a pictorial review. Insights Imaging (2011) 0.81
Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis. Arthritis Rheumatol (2014) 0.81
MRI bone oedema scores are higher in the arthritis mutilans form of psoriatic arthritis and correlate with high radiographic scores for joint damage. Arthritis Res Ther (2009) 0.80
Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography. Clin Rheumatol (2010) 0.80
Spinal inflammation by magnetic resonance imaging in patients with ankylosing spondylitis: association with disease activity and outcome parameters. Rheumatol Int (2011) 0.79
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]. Z Rheumatol (2014) 0.78
Non-invasive imaging demonstrates clinical features of ankylosing spondylitis in a rat adjuvant model: a case study. Eur J Histochem (2016) 0.76
Tools for monitoring spondyloarthritis in clinical practice. Nat Rev Rheumatol (2009) 0.75
Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Res Ther (2016) 0.75
The time-averaged inflammatory disease activity estimates the progression of erosions in MRI of the sacroiliac joints in ankylosing spondylitis. Clin Rheumatol (2012) 0.75
How does imaging help the clinician in the evaluation and management of spondyloarthritis? Skeletal Radiol (2008) 0.75
[MRI examinations for axial and peripheral spondyloarthritis]. Z Rheumatol (2012) 0.75
[Inflammatory spinal diseases: axial spondyloarthritis : Central importance of imaging]. Z Rheumatol (2017) 0.75
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
Clinical history as a screening test for ankylosing spondylitis. JAMA (1977) 3.60
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum (2003) 3.47
Epidemiology of vertebral fractures in women. Am J Epidemiol (1989) 3.27
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am (1998) 1.86
Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis (2004) 1.56
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Imaging and scoring in ankylosing spondylitis. Best Pract Res Clin Rheumatol (2002) 1.44
Radiological scoring methods in ankylosing spondylitis. Reliability and change over 1 and 2 years. J Rheumatol (2004) 1.42
Thoracolumbar spine mechanics contrasted under compression and shear loading. J Orthop Res (2002) 0.99
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum (1998) 6.16
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet (2002) 6.12
The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis (2010) 5.24
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum (2001) 4.57
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet (1996) 4.20
OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage (2004) 4.01
Evaluation of clinically relevant changes in patient reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis (2004) 3.95
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
The natural history of recovery for the healthcare provider "second victim" after adverse patient events. Qual Saf Health Care (2009) 3.79
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum (1999) 3.42
Long-term pacing in sinus node disease: effects of stimulation mode on cardiovascular morbidity and mortality. Am Heart J (1988) 3.33
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA (1997) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum (1995) 3.10
Blindsight in normal observers. Nature (1995) 3.07
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
Neuronal activity in human primary visual cortex correlates with perception during binocular rivalry. Nat Neurosci (2000) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis (2003) 2.85
Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology (2004) 2.81
Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature (2000) 2.81
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum (2003) 2.78
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis (2009) 2.76
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum (2008) 2.71
Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis (2011) 2.67
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. Arthritis Rheum (2007) 2.66
Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clin Neuropsychol (1999) 2.65
Results of provider self-adjudication using the prudent layperson standard compared with the managed care organization's emergency department claim review process. Ann Emerg Med (2000) 2.64
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis (2008) 2.61
Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis (2004) 2.60
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Two distinct mechanisms for redistribution of lymphocyte surface macromolecules. I. Relationship to cytoplasmic myosin. J Cell Biol (1978) 2.54
Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis (2003) 2.48
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol (2000) 2.45